CGGRGD TFA (1260223-44-6 free base)
CAS No. ——
CGGRGD TFA (1260223-44-6 free base)( —— )
Catalog No. M30367 CAS No. ——
CGGRGD TFA is synthesized via solid-phase peptide synthesis technique and the surface of PCL fibers is aminolysised by amino 2-cyanobenzothiazole followed by the addition of 2-cyanobenzothiazole (CBT).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
Biological Information
-
Product NameCGGRGD TFA (1260223-44-6 free base)
-
NoteResearch use only, not for human use.
-
Brief DescriptionCGGRGD TFA is synthesized via solid-phase peptide synthesis technique and the surface of PCL fibers is aminolysised by amino 2-cyanobenzothiazole followed by the addition of 2-cyanobenzothiazole (CBT).
-
DescriptionCGGRGD TFA is synthesized via solid-phase peptide synthesis technique and the surface of PCL fibers is aminolysised by amino 2-cyanobenzothiazole followed by the addition of 2-cyanobenzothiazole (CBT).(In Vitro):CGGRGD TFA is a characteristic sequence of fifibronectin that binds to the receptors on cell surface. (PCL) is a popular materials for tissue engineering due to its optimal biocompatibility, biodegradability, and thermoplastic characteristics.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number——
-
Formula Weight677.61
-
Molecular FormulaC21H34F3N9O11S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical NameSequence:{Cys}{Gly}{Gly}{Arg}{Gly}{Asp}
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
Wenting Zhen, et al.Functionalization of PCL fibrous membrane with RGD peptide
molnova catalog
related products
-
DRB18
DRB18 is a highly effective pan-class inhibitor of glucose transporter proteins (GLUT). It significantly modulates energy-related metabolism in A549 cells by inducing alterations in the abundance of metabolites associated with glucose-related pathways.
-
L-JNKI-1
L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK, it has been shown to effectively inhibit JNK activity in in vivo studies.
-
Nimustine Hydrochlor...
Nimustine has been used in trials studying the treatment of Glioblastoma.
Cart
sales@molnova.com